Sudden! The general manager of a multinational pharmaceutical company in China has left his appointment

Sammy Karam, Abbott's senior vice president and head of emerging markets for the pharmaceutical business, announced the news to employees that Mr Kim would leave Abbott to seek other career opportunities, with the last working day on March 5.
has not yet announced a successor to the general manager of Abbott Pharmaceuticals China, which is temporarily managed by Sammy Karam, head of emerging markets at Abbott Pharmaceuticals.
joined Abbott as General Manager of Abbott EPD China on February 20, 2019 and was the head of Merck's China Pharmaceuticals and Endocrinology Division before joining Abbott, officially leaving Merck on February 15, 2019.
has previously introduced the well-known professional manager, who also started as a pharmaceutical representative when he entered the business, all the way to his current position.
according to industry rumors, after leaving Abbott, Jin Fangxuan will join another multinational pharmaceutical company as general manager of China, I believe there will soon be official news.
about Jin Fang, a graduate of Shanghai Normal University, with 16 years of experience in Merca East and 6 years of merck, from pharmaceutical representative to BU head.
after graduating in 1996, he joined Mercedon as a pharmaceutical representative, then as a regional manager, RPM, in 2002 as a regional manager, then in BD, marketing departments, in 2008 as antimicrobial marketing manager, marketing director, in 2010 as Merca East Women's Health Division Director.
May 2013, Jin Fangji entered Merck China as head of the Endocrinology and Metabolism Division, leading the GWA team from joint promotion with Shi Guibao to return to Merck in 2016, maintaining years of continuous good growth.
On July 31, 2017, Chen Shaofeng, head of Merck's China Pharmaceutical Division, officially left his post to join Roche China as Vice President of The Anti-Infection and Special Medicines Division, after which Merck China Pharmaceuticals and Endocrinology and Metabolism merged, and Jin Fang, then Head of Endocrinology and Metabolism, was appointed head of the new Pharmaceutical and Endocrinology Division.
Abbott Pharmaceuticals China General Manager was previously Renaud Gabay, and on December 5 last year, Abbott announced that Garreno, the former general manager of Abbott Pharmaceuticals China, would serve as Vice President of Abbott Nutrition North Asia, reporting to Daniel Salvadori, Executive Vice President of Abbott Nutrition, that his work would now shift to Abbott Nutrition North Asia, and that he would be formally appointed as successor on January 1, 2019.
February 11, 2019, Peter Huang, Vice President, Asia Pacific, Abbott Pharmaceuticals, announced yesterday the appointment of Kim Fang-chi as General Manager of Abbott Pharmaceuticals China, effective February 20, 2019.